Skip to main content
Caplight Logo









Acclaro Medical

Acclaro Medical

Private
Smithfield, Rhode IslandHealthcare & Life Scienceshttps://ultraclearlaser.com/

Last Round

Series B

May 29, 2025

Total Funding Raised

$23M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Acclaro Medical is a medical technology company that develops and markets energy-based medical solutions, including the UltraClear and AuraLux fiber laser systems for aesthetic and surgical applications.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Fashion & Beauty

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

medical laserskin resurfacingfiber laseraesthetic laserlaser skin rejuvenationdermatology lasercold lasermedical device manufactureraesthetic medicinelaser facialmed spa equipmentablative lasernon-ablative laserskin tighteninglaser scar treatment

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Acclaro Medical Comparables

Compare Acclaro Medical with similar companies based on industry and business-model similarity.

Acclaro Medical comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AVAVA
87%
Sciton, Inc.
85%
Aerolase
84%

Acclaro Medical Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMay 29, 2025

Key People

Founding team and executive leadership

Helen F.

Chief Executive Officer

Executive Team

Ally Jin

Chief Financial Officer

Executive Team

Acclaro Medical Investors

Notable investors and investment history

Acclaro Medical investors
InvestorRounds
Bencao CapitalSeries B
AccelmedSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Grew 15% QoQ, from 112 to 129 employees.

  • Jul 20, 2026

    Grew 22% QoQ, from 104 to 127 employees.

Acclaro Medical Filings

Explore SEC and related filing metadata, where available.

Acclaro Medical filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Acclaro Medical's valuation, stock price, and market status.

Is Acclaro Medical a public or private company?

Acclaro Medical is a private company.

What is the current stock price of Acclaro Medical?

Acclaro Medical is a private company with no public stock price. No recent secondary market data is available.

How much is Acclaro Medical worth (valuation)?

Valuation information for Acclaro Medical is not publicly available.

Can I buy Acclaro Medical stock?

Acclaro Medical shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Acclaro Medical's last funding round?

Acclaro Medical's most recent funding round was Series B on May 29, 2025.

Who are the main investors in Acclaro Medical?

Key investors in Acclaro Medical include Accelmed.

Will Acclaro Medical IPO soon?

No public IPO plans have been announced for Acclaro Medical.

How can I track Acclaro Medical secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Acclaro Medical's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersSmithfield, Rhode Island
Employee Range107
Year Founded2018
Last FundingMay 29, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?